![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, December 19, 2012 2:03:54 PM
(1) Anything with a 90% similarity (homology) to MANF is considered to have the same characteristics that the AMBS patents cover. So if they alter GDNF during phase II trials and it has a similar structure then they have to talk to AMBS about licensing it. If anyone wants to alter CDNF or MANF during testing they have to talk to AMBS about licensing it. There is a reason Hermo Pharma challenged their patents and why the co-founder of Amgen said "MANF could be the biggest success I have ever seen."
(2) Right now MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing. AMBS is only valued at $12 Million
You can try to get cute with flipping your shares but the moment a JV is announced you're not going to be able to get in. There is a reason the co-founder of Amgen is here. There is a reason senior executives of Bayer and Bristol Myers are here. They are not going to waste their time with something that they haven't done the research on.
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM